Sign Up Today and Learn More About Freenome Stock
Invest in or calculate the value of your shares in Freenome or other pre-IPO companies through EquityZen's platform.
Freenome Stock (FREN)
Multiomics Platform for Early Disease Screening
About Freenome Stock
Founded
2015
Headquarters
South San Francisco, CA, US
Total Funding
77.5M
Industries
Software, Artificial Intelligence, Data and Analytics
Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.
Freenome Press Mentions
Stay in the know about the latest news on Freenome
Top 10 Liquid Biopsy Companies in the World [2025]
prlog • Dec 25, 2024
Freenome Announces CEO Transition
prnewswire • Sep 25, 2024
Longevity Startups Are Getting Funding, But Not As Fast As We’re Aging
news • Sep 23, 2024
Bay Area tech layoffs: Cancer screening company to cut 20% of workforce after securing $254 million
sfchronicle • Jun 26, 2024
Freenome to cut more than 100 employees in restructuring
finance • May 23, 2024
Investors in Freenome
Discover investors in Freenome stock and explore their portfolio companies
Freenome Management
Leadership team at Freenome
Chief Executive Officer
Mike Nolan
Chief Financial Officer
William Quirk
Join now and verify your accreditation status to gain access to:
- Freenome current valuation
- Freenome stock price
- Available deals in Freenome and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Freenome Stock
How to invest in Freenome stock?
Accredited investors can buy pre-IPO stock in companies like Freenome through EquityZen funds. These investments are made available by existing Freenome shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Freenome stock?
Shareholders can sell their Freenome stock through EquityZen's private company marketplace. EquityZen's network includes over 340K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 44K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
